The second CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held at the Babraham Institute, Cambridge, 4th and 5th March 2020. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in Drug Discovery meeting will include:

Large-scale CRISPR functional genomics studies for drug target identification and validation
Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models
Cutting edge CRISPR genome engineering technologies and their emerging applications
A perspective from technology leaders toward the future therapeutic applications of genome engineering
We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech, and CRO’s to hear talks given by speakers at the cutting edge of genome engineering, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

Venue: Babraham Research Campus
Location: The Cambridge Building, Babraham Research Campus, Cambridge
Country: United Kingdom

Organiser Contact Details:

T: 07484 113971

Press Releases

Horizon Discovery to provide access to novel base editing technology
Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio
Horizon Discovery signs collaboration and license agreement with Mammoth Biosciences

CRISPR in Drug Discovery 2020
Babraham Research Campus
The Cambridge Building, Babraham Research Campus, Cambridge Hotels nearby

Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2003-2020